Veeral S. Sheth

Veeral S. Sheth

Ophthalmology

6320 W 159th St
Oak Forest, IL 60452

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Summary of Research: Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial.

Summary of Research: Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial.

Journal: Ophthalmology and therapy

Published: April 15, 2026

Four-Year Outcomes of Faricimab in Diabetic Macular Edema in the RHONE-X Extension Trial: A Podcast.

Four-Year Outcomes of Faricimab in Diabetic Macular Edema in the RHONE-X Extension Trial: A Podcast.

Journal: Ophthalmology and therapy

Published: April 15, 2026

Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naïve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study.

Aqueous Humor Biomarkers, Efficacy, and Safety in Patients with Naïve Diabetic Macular Edema Treated with Faricimab: The ALTIMETER Study.

Journal: Ophthalmology science

Published: October 17, 2025

Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial.

Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results from the RHONE-X Extension Trial.

Journal: Ophthalmology

Published: October 14, 2025

Does the Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema in Randomized Trials Translate into Real-World Settings?

Does the Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema in Randomized Trials Translate into Real-World Settings?

Journal: Ophthalmology and therapy

Published: July 10, 2025

Reply to Comment on Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Reply to Comment on Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Journal: American journal of ophthalmology

Published: April 25, 2025

Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial.

Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial.

Journal: JAMA ophthalmology

Published: March 06, 2025

Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Journal: American journal of ophthalmology

Published: December 09, 2024

Phase I Study of the Anti-interleukin 33 Fragment Antigen-Binding Region RO7303359 in Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Phase I Study of the Anti-interleukin 33 Fragment Antigen-Binding Region RO7303359 in Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Journal: Ophthalmology science

Published: August 28, 2024

Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices.

Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices.

Journal: JAMA ophthalmology

Published: June 27, 2024

Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study.

Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study.

Journal: Eye (London, England)

Published: May 22, 2024

Quantifying Fluid and Function in Suboptimal Responders Switched From an Anti-vascular Endothelial Growth Factor (VEGF) to Faricimab.

Quantifying Fluid and Function in Suboptimal Responders Switched From an Anti-vascular Endothelial Growth Factor (VEGF) to Faricimab.

Journal: Cureus

Published: March 20, 2024

Showing 1-12 of 44

Last Updated: 09/26/2026